{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"2.76","value":"0.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Complete Hematological Response (CHR) was defined as\n\n* WBC count \\<10×109/L\n* platelet count \\<450×109/L\n* basophils \\<5%\n* no blasts and promyelocytes in peripheral blood\n* myelocytes+metamyelocytes \\<5% in peripheral blood\n* no evidence of extramedullary disease, including spleen and liver\n* Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"from first dosing to CHR, UP TO 66 CYCLES","title":"Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients","type":"SECONDARY","unitOfMeasure":"months"}